Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Slate Path Capital David Greenspan | 1,329,000 | $40,667,400 | 0.9% | |
| 2. | Rokos Capital Management Chris Rokos | 1,229,148 | $37,630,366 | -27% | 0.32% |
| 3. | VenBio Select Advisor Kurt Von Emster | 1,130,000 | $34,578,000 | +100% | 0.47% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 927,187 | $28,371,922 | +98% | 0.3% |
| 5. | Aquilo Capital Management Marc Schneidman | 908,474 | $27,799,304 | 17.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.50 | 1,000 | Director | 33,680 | 2024-03-20 | Filing | |
| $28.00 | 1,000 | Director | 32,680 | 2024-03-19 | Filing | |
| $27.49 | 1,000 | Director | 31,680 | 2024-03-18 | Filing | |
| $66.37 | 655 | Director | 109,868 | 2021-12-28 | Filing | |
| $50.00 | 500 | Director | 17,500 | 2020-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.03 | 6,000 | Officer | 204,851 | 2024-04-01 | Filing | |
| $35.19 | 40,000 | Officer | 400,600 | 2024-03-06 | Filing | |
| $32.71 | 19,730 | Officer, Director | 3,715,048 | 2024-01-31 | Filing | |
| $32.16 | 37,769 | Officer, Director | 3,734,778 | 2024-01-31 | Filing | |
| $37.37 | 3,702 | Officer | 210,851 | 2024-01-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,303,757 | $407,094,965 | 0.01% | |
| 2. | 10,672,076 | $326,565,525 | 0% | |
| 3. | 6,825,111 | $208,848,397 | 0.01% | |
| 4. | 3,371,268 | $103,160,815 | 0% | |
| 5. | 2,751,048 | $84,182,068 | 0% |
News See All
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.
12 High Growth Healthcare Stocks to Buy
The healthcare sector proved its mettle in 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.
Billionaire Hedge Funds
